BRAF and melanoma: This is of particular interest since several of the currently proposed drug resistance mechanisms against melanoma, through upregulation of C-Raf [46], B-Raf [47], hepatocyte growth factor [48] or PDGFR [49], reactivate the signaling pathways which are mediated by SHP2.